New drug combo aims to boost stem cell transplant success in older blood cancer patients

NCT ID NCT07396480

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding the targeted drug venetoclax to standard chemotherapy (fludarabine and melphalan) before a donor stem cell transplant can improve outcomes for patients over 50 with acute myeloid leukemia or myelodysplastic syndrome. The study will compare the new three-drug regimen against the standard two-drug regimen in 186 participants. The goal is to reduce relapse and improve survival without increasing severe graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a targeted pill) added to fludarabine and melphalan chemotherapy
What this could lead to: If successful, this could become a new standard conditioning regimen before stem cell transplant for older AML/MDS patients, improving long-term survival and reducing relapse.
What could go wrong: This is an early-phase 3 trial with 186 participants, so results are not yet proven. Adding venetoclax may increase side effects like infections or organ toxicity, and the benefit over standard chemo is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic/myeloproliferative neoplasm myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUCEMIA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CONDITIONING MYELDYSPLASTIC SYNDROME (MDS) MYELOID MALIGNANCIES VENENTOCLAX

Contacts and locations

Locations

Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
RECRUITING

Nanjing, Jiangsu, China
Nanfang Hospital Southern Medical University
RECRUITING

Guangzhou, Guangdong, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, China
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
RECRUITING

Chongqing, China
Shanghai General Hospital (Shanghai First People's Hospital)
RECRUITING

Shanghai, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
The Affiliated People's Hospital of Ningbo University
RECRUITING

Ningbo, China
The First Affiliated Hospital of Fujian Medical University
RECRUITING

Fuzhou, Fujian, China
The First Affiliated Hospital of Ningbo University
RECRUITING

Ningbo, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, China
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
RECRUITING

Hangzhou, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
Xiangya Hospital Central South University
RECRUITING

Changsha, Hunan, China
Zhejiang Cancer Hospital & Hangzhou Institute of Medicine, Chinese Academy of Sciences
RECRUITING

Hangzhou, Zhejiang, China
Zhejiang Provincial Peoples's Hospital
RECRUITING

Hangzhou, China
the First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 311121, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.